Akeso Biopharma (Cayman) Limited ("Akeso") announced that the general authorization for the allotment and issuance of new shares was completed on October 21, 2024. The company successfully allotted 31,700,000 new shares at a price of 61.28 Hong Kong dollars per share to no fewer than six independent professional, institutional, or other investors. Following this allotment, the company's enlarged issued share capital increased by approximately 3.53%. Akeso Biopharma received net proceeds of approximately 1,924.2 million Hong Kong dollars from the allotment, which will be used in accordance with the previously announced purposes. After the allotment, the board of directors of the company comprises seven members, including Dr. Xia Yu, Chairman and Executive Director.

Akeso Biopharma (Cayman) Limited ("Akeso") announced that the general authorization for the allotment and issuance of new shares was completed on October 21, 2024. The company successfully allotted 31,700,000 new shares at a price of 61.28 Hong Kong dollars per share to no fewer than six independent professional, institutional, or other investors. Following this allotment, the company's enlarged issued share capital increased by approximately 3.53%. Akeso Biopharma received net proceeds of approximately 1,924.2 million Hong Kong dollars from the allotment, which will be used in accordance with the previously announced purposes. After the allotment, the board of directors of the company comprises seven members, including Dr. Xia Yu, Chairman and Executive Director.